ClinicalTrials.gg
CompletedNCT00456092Updated Jun 19, 2020Results posted

Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis

A Phase 2 interventional study of Apremilast and Placebo in Psoriatic Arthritis, sponsored by Amgen. Completed at 38 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-19.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.

Enrollment
10th of 17
204 · median 219
Started
2007
the only one that year
Phase 2
2 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
11 of 17
Amgen

Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 10th largest by enrollment, is the only one that started in 2007, is one of 2 in phase 2, and was the 1st registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing apremilast in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.

Read the detailed description

Prior to the implementation of Amendment 1/UK3 the study consisted of 3 phases - pre-randomization up to 35 days, up to 84 days placebo-controlled treatment and a 28-day observational follow up. After the implementation of Amendment 1/UK3, the study consisted of 4 phases - pre-randomization up to 35 days, up to 84 days treatment in the placebo controlled treatment phase, up to 84 days treatment in the active treatment extension phase and a 28 day follow up. Participants who completed the treatment phase prior to implementation of amendment 1/UK3 did not have the option of entering the extension phase.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

Keywords

  • psoriatic arthritis
  • ACR
  • PASI
  • DAS
  • pharmacokinetic
  • biopsy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of psoriatic arthritis (Moll and Wright Criteria), including symmetrical or asymmetrical peripheral joint involvement for at least 6 months
  • Active psoriatic arthritis at the time of screening and baseline as defined by: 3 or more swollen joints AND 3 or more tender joints
  • Negative rheumatoid factor (RF)
  • If using methotrexate, be on methotrexate for at least 168 days (24 weeks) and be on a stable dose for at least 56 days prior to screening and throughout the study
  • If using oral , be on a stable dose of prednisone ≤ 10 mg/day or equivalent for at least 28 days prior to screening and throughout the study
  • If using nonsteroidal anti-inflammatory drug (NSAID) therapy, be on a stable dose for at least 14 days prior to screening and throughout the study
  • Must meet the following laboratory criteria:

    • ≥ 9 g/dL
    • Hematocrit ≥ 27%
    • White blood cell (WBC) count ≥ 3000/μL (≥ 3.0 X 10\^9/L) and \< 20,000/μL (\< 20 X 10\^9/L)
    • Neutrophils ≥ 1500 /μL (≥ 1.5 X 10\^9/L)
    • ≥ 100,000 /μL (≥ 100 X 10\^9/L)
    • Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)
    • Total ≤ 2.0 mg/dL
    • (AST [serum glutamic oxaloacetic transaminase, SGOT]) and alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) ≤ 1.5x (ULN)
  • Females of (FCBP) must have a negative urine pregnancy test at screening (Visit 1). In addition, sexually active FCBP must agree to use TWO adequate forms of while on study medication. A FCBP must agree to have pregnancy tests every 28 days while on study medication
  • Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP while on study medication and for at least 84 days after taking the last dose of study medication

Exclusion criteria

Exclusion Criteria:

History of any cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases

  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Pregnant or lactating female
  • History of active Mycobacterium tuberculosis infection (any subspecies) within 3 years prior to the screening visit. Infections that occurred > 3 years prior to entry must have been effectively treated.
  • History of incompletely treated latent Mycobacterium tuberculosis infection (as indicated by a positive Purified Protein Derivative [PPD] skin test or in vitro test [T SPOT®.TB, QuantiFERON Gold®])
  • Clinically significant abnormality on the chest x-ray (CXR) at screening
  • Current erythrodermic, guttate, or pustular forms of psoriasis
  • History of infected joint prosthesis within the past 5 years
  • Systemic therapy for psoriasis and/or psoriatic arthritis (except for methotrexate, ≤ 10 mg/day prednisone or equivalent, and NSAIDs) including, but not limited to, sulfasalazine, leflunomide, chloroquine, hydroxychloroquine, gold compounds, parenteral (including intra-articular), penicillamine, cyclosporine, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, tacrolimus, azathioprine, and fumaric acid esters within 28 days of randomization and throughout the study
  • Topical therapy for the treatment of psoriasis including, but not limited to topical steroids, topical vitamin A or D analog preparations, tacrolimus, pimecrolimus, or anthralin within 14 days of randomization (Note: Topical background therapy for treatment of psoriasis is allowed, except within 24 hours of a study visit, as follows: mild or moderate potency corticosteroids for treatment of the palms, face, scalp, axillae, plantar surfaces, and groin in accordance with the manufacturer's suggested usage. Nonmedicated emollients [eg, Eucerin®] and tar shampoo are also allowed.)
  • Phototherapy (ultraviolet light A [UVA], narrow-band ultraviolet light B [NB-UVB], psoralens and long-wave ultraviolet radiation [PUVA]) within 28 days prior to randomization
  • Etanercept use within 56 days prior to randomization
  • Adalimumab, efalizumab, or infliximab use within 84 days prior to randomization
  • Alefacept use within 168 days (24 weeks) prior to randomization
  • Use of intra-articular corticosteroids within 28 days prior to randomization
  • Use of any medication within 28 days prior to randomization or 5 half-lives if known (whichever is longer)
  • Any clinically significant abnormality on 12-lead (ECG) at screening
  • High-risk factor(s) for, or a history of, (HIV), , or virus infection
  • History of within previous 5 years (except for treated basal-cell skin carcinoma(s) and/or fewer than 3 treated squamous-cell skin carcinomas)
  • Evidence of skin conditions at the time of screening visit that would interfere with evaluations of the effect of study medication on psoriasis
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    Apremilast 40 mg QD

    Participants received 40 mg apremilast orally once a day (QD) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 40 mg apremilast QD for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 40 mg QD thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.

    Drug: Apremilast

  • Experimental
    Apremilast 20 mg BID

    Participants received 20 mg apremilast orally twice a day (BID) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 20 mg apremilast BID for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 20 mg BID thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.

    Drug: Apremilast

  • Placebo comparator
    Placebo

    Participants received matching placebo to apremilast orally BID for 12 weeks during the Treatment Phase. Participants who entered the Extension Phase were re-randomized on Day 85 to receive either 40 mg apremilast QD or 20 mg apremilast BID for 12 weeks.

    Drug: Placebo

Interventions

  • Capsules for oral administration

    Also known as: CC-10004, Otezla®

  • DrugPlacebo

    Capsules for oral administration

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12

    A modified American College of Rheumatology 20% (ACR 20) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 20% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Number of Participants With Adverse Events During the Treatment Phase

    The severity of each adverse event (AE) was graded based upon the participant's symptoms according to National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE, Version 3.0), on a scale from 1 (Mild AE) to 5 (Death due to AE). Severe AEs are defined as NCI CTCAE grade 3 or higher. AEs related to study drug are those determined by the investigator as suspected to be related to study drug where a temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other medications, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. A serious adverse event (SAE) is any AE which: - Resulted in death - Was life-threatening - Required inpatient hospitalization or prolongation of existing hospitalization - Resulted in persistent or significant disability/incapacity - Was a congenital anomaly/birth defect - Constituted an important medical event.

    Time frame: 12 weeks

  2. Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 12

    A PsARC response is defined as improvement from Baseline in at least 2 of the following 4 measures, at least 1 of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures, according to the following: • At least 30% improvement in the 78 tender joint count, • At least 30% improvement in the 76 swollen joint count, • At least 20% improvement in the patient global assessment of disease activity, measured on a 100 mm visual analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • At least 20% improvement in the physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Participants with no post-baseline PsARC scores were considered non-responders.

    Time frame: Baseline and Week 12

  3. Percentage of Participants With a Modified ACR 50 Response at Week 12

    A modified American College of Rheumatology 50% (ACR 50) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 50% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.

    Time frame: Baseline and Week 12

  4. Percentage of Participants With a Modified ACR 70 Response at Week 12

    A modified American College of Rheumatology 70% (ACR 70) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 70% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.

    Time frame: Baseline and Week 12

  5. Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response Based on Disease Activity Score (DAS28)-CRP(4) at Week 12

    The DAS28 measures the severity of disease at a specific time. DAS28-CRP(4) is derived from the following 4 variables: • 28 tender joint count, (TJC; does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count (SJC) • C-reactive protein (CRP) • Patient's global assessment of disease activity (GH) according to the formula: DAS28-CRP(4) = 0.56\*√(TJC28) + 0.28\*(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2

    Time frame: Baseline and Week 12

  6. Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 12

    The DAS28 measures the severity of disease at a specific time. DAS28-CRP(3) is derived from the following 3 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) according to the formula: DAS28-CRP(3) = \[0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.36\*ln(CRP+1)\] \* 1.10 + 1.15. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2

    Time frame: Baseline and Week 12

  7. Percentage of Participants With DAS28-CRP(4) Score of Mild Disease Activity or In Remission at Week 12

    The DAS28-CRP(4) measures the severity of disease derived from the following 4 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28-CRP(4) scores range from 0 to 9.4, where higher scores indicate more disease activity. Mild disease severity is defined as a DAS28-CRP(4) score of ≤ 3.2. In remission is defined as a DAS28-CRP(4) score of ≤ 2.6.

    Time frame: Week 12

  8. Percentage of Participants With DAS28-CRP(3) Score of Mild Disease Activity or In Remission at Week 12

    The DAS28-CRP(3) measures the severity of disease derived from the following 3 variables: • 28 tender joint count (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) DAS28-CRP(3) scores range from 0 to 9.4, where higher scores indicate more disease activity. Mild disease severity is defined as a DAS28-CRP(3) score of ≤ 3.2. In remission is defined as a DAS28-CRP(3) score of ≤ 2.6.

    Time frame: Week 12

  9. Number of Participants Who Withdrew Prematurely Due to Lack of Efficacy

    The number of participants who withdrew prematurely from the treatment phase due to lack of efficacy, including flare of psoriasis, flare of psoriatic arthritis or worsening or not responding to study treatment.

    Time frame: Baseline to Week 12

  10. Number of Participants With Adverse Events Leading to a Dose Reduction

    The number of participants who were dose reduced during the treatment phase due to adverse events.

    Time frame: Baseline to Week 12

  11. Maximal ACR Response During the Treatment Phase

    The ACR-N index score was calculated for each participant at each time point in the study according to the following definition: ACR-N = the lowest of the following 3 values: - percent improvement from Baseline in the 76 swollen joint count, - percent improvement from Baseline in the 78 tender joint count - median percent improvement from Baseline in the following 5 measures ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. The maximal ACR-N for each participant during the 12-week treatment period was calculated, and represents the maximal ACR response achieved.

    Time frame: ACR was measured at Baseline and Weeks 2, 4, 6, 8, 10, and 12

  12. Time to ACR 20 Response During the Treatment Phase

    The Kaplan-Meier estimates of time to ACR 20 response was calculated for participants who had an ACR 20 response at any time during the treatment phase.

    Time frame: Baseline to Week 12

  13. Time to ACR 50 Response During the Treatment Phase

    The Kaplan-Meier estimates of time to ACR 50 response was calculated for participants who had an ACR 50 response at any time during the treatment phase.

    Time frame: Baseline to Week 12

  14. Time to ACR 70 Response During the Treatment Phase

    The Kaplan-Meier estimates of time to ACR 70 response was calculated for participants who had an ACR 70 response at any time during the treatment phase.

    Time frame: Baseline to Week 12

  15. Change From Baseline in Dactylitis Severity Score at Week 12

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated on a scale from 0 (no dactylitis) to 3 (severe dactylitis). The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 60.

    Time frame: Baseline and Week 12

  16. Percentage of Participants With Enthesitis

    Enthesitis is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Enthesitis is characterized by swelling, pain, and tenderness around the calcaneous, and occasionally by effusion in the bursa associated with this joint. The enthesitis assessment is an evaluation of inflammation at the insertions of the Achilles tendon into the calcaneous and of the plantar fascia into the calcaneous. Inflammation at 1 or more insertions on either the right or left side constituted a positive assessment.

    Time frame: Baseline and Week 12

  17. Time to Relapse of Psoriatic Arthritis During the Observational Follow-up Phase

    Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Observation Phase in participants who received apremilast and achieved at least an ACR 20 at their Final Treatment Phase/Early Termination Visit. The time to relapse during the Observational Phase was calculated from the time of maximum ACR reduction and from the date of the Final Treatment Phase visit. Participants classified as responders who did not relapse were censored at the day of the last follow-up.

    Time frame: From Week 12 to end of 28-day observational follow-up (1) and from the date of maximal ACR during the 12-week Treatment Phase until the end of the 28-day observational follow-up phase (2).

  18. Number of Participants Who Relapsed During the Observational Follow-up Phase

    Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Observation Phase in participants who received apremilast and achieved at least an ACR 20 at their Final Treatment Phase/Early Termination Visit.

    Time frame: 28-day observational follow-up period following Week 12

  19. Change From Baseline in Short Form 36 (SF-36) Summary Physical and Mental Component Scores at Week 12

    The Medical Outcome SF 36-Item Health Survey, Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The summary physical health score included the following subscales: physical functioning, role-physical, bodily pain, and general health. The summary mental health score included other subscales: vitality, social functioning, role-emotional, and mental health. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10, where higher scores are associated with better functioning/quality of life. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale. A higher change from baseline indicates an improvement in better health results or functioning.

    Time frame: Baseline and Week 12

  20. Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12

    The DLQI is a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on participants' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Each question is answered on a scale from 0 (not at all) to 3 (very much). The total score ranges from 0 to 30 where a higher score indicates that a participant's dermatological condition has a greater impact on their daily life.

    Time frame: Baseline and Week 12

  21. Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

    The HAQ-DI is a self-administered instrument consisting of 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item asks over the past week whether a particular task can be performed. For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). The eight category scores are averaged into an overall HAQ-DI score on a scale from zero (no disability) to three (completely disabled).

    Time frame: Baseline and Week 12

  22. Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 12

    The FACIT-Fatigue is a 13 item self-administered questionnaire that assesses both the physical and functional consequences of fatigue based on recall during the past 7 days. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The total score ranges from 0 to 52 with higher scores representing less fatigue.

    Time frame: Baseline and Week 12

  23. Number of Participants With Adverse Events During the Extension Phase

    The severity of each adverse event (AE) was graded based upon the participant's symptoms according to National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE, Version 3.0), on a scale from 1 (Mild AE) to 5 (Death due to AE). Severe AEs are defined as NCI CTCAE grade 3 or higher. AEs related to study drug are those determined by the investigator as suspected to be related to study drug where a temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other medications, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. A serious adverse event (SAE) is any AE which: - Resulted in death - Was life-threatening - Required inpatient hospitalization or prolongation of existing hospitalization - Resulted in persistent or significant disability/incapacity - Was a congenital anomaly/birth defect - Constituted an important medical event.

    Time frame: Weeks 12 to 24 (Extension Phase)

  24. Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

    A PsARC response is defined as improvement from Baseline in at least 2 of the following 4 measures, at least 1 of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • At least 30% improvement in the 78 tender joint count, • At least 30% improvement in the 76 swollen joint count, • At least 20% improvement in the patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • At least 20% improvement in the physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Participants with missing data were considered non-responders.

    Time frame: Baseline and Week 24

  25. Percentage of Participants With a Modified ACR 20 Response at Week 24

    A modified ACR 20 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 20% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1) and from Week 12 (Day 85). Participants with no post-baseline ACR scores were considered non-responders.

    Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24

  26. Percentage of Participants With a Modified ACR 50 Response at Week 24

    A modified ACR 50 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 50% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1) and from Week 12 (Day 85). Participants with no post-baseline ACR scores were considered non-responders.

    Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24

  27. Percentage of Participants With a Modified ACR 70 Response at Week 24

    A modified ACR 70 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 70% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1). Participants with no post-baseline ACR scores were considered non-responders.

    Time frame: Baseline (Day 1) and Week 24

  28. Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(4) at Week 24

    The DAS28 measures the severity of disease at a specific time. DAS28-CRP(4) is derived from the following 4 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein • Patient's global assessment of disease activity according to the formula: DAS28-CRP(4) = 0.56\*√(TJC28) + 0.28\*(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2

    Time frame: Baseline and Week 24

  29. Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 24

    The DAS28 measures the severity of disease at a specific time. DAS28-CRP(3) is derived from the following 3 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) according to the formula: DAS28-CRP(3) = \[0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.36\*ln(CRP+1)\] \* 1.10 + 1.15. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2

    Time frame: Baseline and Week 24

  30. Maximal ACR Response During the Extension Period

    The ACR-N index score was calculated for each participant at each time point in the study according to the following definition: ACR-N = the lowest of the following 3 values: • percent improvement from Baseline in the 76 swollen joint count, • percent improvement from Baseline in the 78 tender joint count • median percent improvement from Baseline in the following 5 measures ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. The maximal ACR-N for each participant during the 12-week extension period was calculated, and represents the maximal ACR response achieved.

    Time frame: ACR was measured at Baseline and Weeks 16, 20 and 24

  31. Time to ACR 20 Response During the Study

    Time to ACR 20 was measured from the first dose of apremilast to the first time a participant achieved an ACR 20 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 20 response were calculated for participants who had an ACR 20 response at any time during the study.

    Time frame: Baseline to Week 24

  32. Time to ACR 50 Response During the Treatment and Extension Phase

    Time to ACR 50 response was measured from the first dose of apremilast to the first time a participant achieved an ACR 50 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 50 response were calculated for participants who had an ACR 50 response at any time during the study.

    Time frame: Baseline to Week 24

  33. Time to ACR 70 Response During the Treatment and Extension Phase

    Time to ACR 70 response was measured from the first dose of apremilast to the first time a participant achieved an ACR 70 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 70 response were calculated for participants who had an ACR 70 response at any time during the study.

    Time frame: Baseline to Week 24

  34. Change From Baseline and Week 12 in Dactylitis Severity Score at Week 24

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated on a scale from 0 (no dactylitis) to 3 (severe dactylitis). The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 60. Change in the dactylitis severity score was assessed from Baseline (Day 1) and from Week 12 (Day 85).

    Time frame: Baseline, Week 12 and Week 24

  35. Percentage of Participants With Enthesitis in the Extension Phase

    Enthesitis is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Enthesitis is characterized by swelling, pain, and tenderness around the calcaneous, and occasionally by effusion in the bursa associated with this joint. The enthesitis assessment is an evaluation of inflammation at the insertions of the Achilles tendon into the calcaneous and of the plantar fascia into the calcaneous. Inflammation at 1 or more insertions on either the right or left side constituted a positive assessment.

    Time frame: Week 12 and Week 24

  36. Time to Relapse of Psoriatic Arthritis After Extension Phase

    Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Follow-up Phase in participants who achieved at least an ACR 20 at their Final Extension Phase (Week 24)/Early Termination Visit. The time to relapse during the Follow-up Phase was calculated from the time of maximum ACR reduction and from the date of the Final Extension Phase visit. Participants classified as responders who did not relapse were censored at the day of the last follow-up.

    Time frame: From Week 24 to the end of the 28-day follow-up (1) and from the date of maximal ACR until the end of the 28-day follow-up phase (2).

  37. Number of Participants Who Relapsed After the Extension Phase

    Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Follow-up Phase in participants who achieved at least an ACR 20 at their Final Extension Phase/Early Termination Visit.

    Time frame: Week 24 to Week 28 (28-day follow-up period)

  38. Change From Baseline and Week 12 in SF-36 at Week 24

    The Medical Outcome SF 36-Item Health Survey, Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The summary physical health score included the following subscales: physical functioning, role-physical, bodily pain, and general health. The summary mental health score included other subscales: vitality, social functioning, role-emotional, and mental health. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10, where higher scores are associated with better functioning/quality of life. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale. A higher change from baseline indicates an improvement in better health results or functioning.

    Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24

  39. Change From Baseline and Week 12 in Dermatology Life Quality Index (DLQI) at Week 24

    The DLQI is a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on participants' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Each question is answered on a scale from 0 (not at all) to 3 (very much) The total score ranges from 0 to 30 where a higher score indicates that a participant's dermatological condition has a greater impact on their daily life.

    Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24

  40. Change From Baseline and Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24

    The HAQ-DI is a self-administered instrument consisting of 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item asks over the past week whether a particular task can be performed. For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). The eight category scores are averaged into an overall HAQ-DI score on a scale from zero (no disability) to three (completely disabled).

    Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24

  41. Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 24

    The FACIT-Fatigue is a 13 item self-administered questionnaire that assesses both the physical and functional consequences of fatigue based on recall during the past 7 days. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The total score ranges from 0 to 52 with higher scores representing less fatigue.

    Time frame: Baseline (Day 1), Week 12 (Day 85) and Week 24

07

Results

Posted Oct 23, 2019

Participant flow

Participants were enrolled across 38 sites in Canada, Belgium, Germany, the Netherlands, and the United Kingdom.

Extension Phase
Participant flow — Extension Phase
MilestoneApremilast 40 mg QDApremilast 20 mg BIDPlaceboPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Started464002020
Completed353601913
Not completed114017
Withdrew: Grade 2 or greater ae22002
Withdrew: Flare of psoriatic arthritis10001
Withdrew: Worsening / not responding to study drug31002
Withdrew: Withdrew consent20000
Withdrew: Lost to follow-up11001
Withdrew: Other20011
Treatment Phase (12 Weeks)
Participant flow — Treatment Phase (12 Weeks)
MilestoneApremilast 40 mg QDApremilast 20 mg BIDPlaceboPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Started67696800
Completed60555000
Not completed7141800
Withdrew: Grade 2 or greater adverse event (ae)34200
Withdrew: Aes not included in nci terminology12000
Withdrew: Intolerability of the study drug20000
Withdrew: Flare of psoriasis01200
Withdrew: Flare of psoriatic arthritis03300
Withdrew: Worsening / not responding to study drug02700
Withdrew: Withdrew consent01200
Withdrew: Lost to follow-up01100
Withdrew: Other10100

Outcome measures

PrimaryPercentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12

A modified American College of Rheumatology 20% (ACR 20) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 20% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 12
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Percentage of Participants With a Modified American College of Rheumatology 20% (ACR 20) Response at Week 1235.843.511.8
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared, Corrected · p = 0.002 (A p-value \< 0.025 (2-sided) is considered statistically significant, after adjusting for two treatment comparisons using the Bonferroni procedure.) · Odds ratio (or): 4.190 · 95% CI 1.72 to 10.20
  • Apremilast 20 mg BID vs Placebo · Chi-squared, Corrected · p = < 0.001 (A p-value \< 0.025 (2-sided) is considered statistically significant, after adjusting for two treatment comparisons using the Bonferroni procedure.) · Odds ratio (or): 5.770 · 95% CI 2.40 to 13.88
SecondaryNumber of Participants With Adverse Events During the Treatment Phase

The severity of each adverse event (AE) was graded based upon the participant's symptoms according to National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE, Version 3.0), on a scale from 1 (Mild AE) to 5 (Death due to AE). Severe AEs are defined as NCI CTCAE grade 3 or higher. AEs related to study drug are those determined by the investigator as suspected to be related to study drug where a temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other medications, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. A serious adverse event (SAE) is any AE which: - Resulted in death - Was life-threatening - Required inpatient hospitalization or prolongation of existing hospitalization - Resulted in persistent or significant disability/incapacity - Was a congenital anomaly/birth defect - Constituted an important medical event.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events During the Treatment Phase
ParticipantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
All adverse events585955
Adverse events related to study drug272626
Severe adverse events546
Severe adverse events related to study drug111
Serious adverse events044
Serious adverse events related to study drug001
Discontinued study drug due to adverse event6107
Discontinued due to AE related to study drug541
SecondaryPercentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 12

A PsARC response is defined as improvement from Baseline in at least 2 of the following 4 measures, at least 1 of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures, according to the following: • At least 30% improvement in the 78 tender joint count, • At least 30% improvement in the 76 swollen joint count, • At least 20% improvement in the patient global assessment of disease activity, measured on a 100 mm visual analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • At least 20% improvement in the physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Participants with no post-baseline PsARC scores were considered non-responders.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 12
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 1250.752.222.1
SecondaryPercentage of Participants With a Modified ACR 50 Response at Week 12

A modified American College of Rheumatology 50% (ACR 50) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 50% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified ACR 50 Response at Week 12
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Percentage of Participants With a Modified ACR 50 Response at Week 1213.417.42.9
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared, Corrected · p = 0.056 · Odds ratio (or): 5.120 · 95% CI 1.06 to 24.67
  • Apremilast 20 mg BID vs Placebo · Chi-squared, Corrected · p = 0.012 · Odds ratio (or): 6.950 · 95% CI 1.49 to 32.35
SecondaryPercentage of Participants With a Modified ACR 70 Response at Week 12

A modified American College of Rheumatology 70% (ACR 70) response was defined as a participant who met the following 3 criteria for improvement from Baseline: • ≥ 70% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); ◦ C-reactive protein. Participants with no post-baseline ACR scores were considered non-responders.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified ACR 70 Response at Week 12
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Percentage of Participants With a Modified ACR 70 Response at Week 127.55.81.5
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared, Corrected · p = 0.204 · Odds ratio (or): 5.400 · 95% CI 0.61 to 47.54
  • Apremilast 20 mg BID vs Placebo · Chi-squared, Corrected · p = 0.371 · Odds ratio (or): 4.120 · 95% CI 0.45 to 37.88
SecondaryPercentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response Based on Disease Activity Score (DAS28)-CRP(4) at Week 12

The DAS28 measures the severity of disease at a specific time. DAS28-CRP(4) is derived from the following 4 variables: • 28 tender joint count, (TJC; does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count (SJC) • C-reactive protein (CRP) • Patient's global assessment of disease activity (GH) according to the formula: DAS28-CRP(4) = 0.56\*√(TJC28) + 0.28\*(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response Based on Disease Activity Score (DAS28)-CRP(4) at Week 12
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response Based on Disease Activity Score (DAS28)-CRP(4) at Week 1249.355.138.2
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared, Corrected · p = 0.264 · Odds ratio (or): 1.568 · 95% CI 0.79 to 3.11
  • Apremilast 20 mg BID vs Placebo · Chi-squared, Corrected · p = 0.071 · Odds ratio (or): 1.980 · 95% CI 1.00 to 3.91
SecondaryPercentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 12

The DAS28 measures the severity of disease at a specific time. DAS28-CRP(3) is derived from the following 3 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) according to the formula: DAS28-CRP(3) = \[0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.36\*ln(CRP+1)\] \* 1.10 + 1.15. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 12
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 1250.744.944.1
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared, Corrected · p = 0.549 · Odds ratio (or): 1.305 · 95% CI 0.66 to 2.57
  • Apremilast 20 mg BID vs Placebo · Chi-squared, Corrected · p = 1.000 · Odds ratio (or): 1.033 · 95% CI 0.53 to 2.03
SecondaryPercentage of Participants With DAS28-CRP(4) Score of Mild Disease Activity or In Remission at Week 12

The DAS28-CRP(4) measures the severity of disease derived from the following 4 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28-CRP(4) scores range from 0 to 9.4, where higher scores indicate more disease activity. Mild disease severity is defined as a DAS28-CRP(4) score of ≤ 3.2. In remission is defined as a DAS28-CRP(4) score of ≤ 2.6.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-CRP(4) Score of Mild Disease Activity or In Remission at Week 12
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Percentage of Participants With DAS28-CRP(4) Score of Mild Disease Activity or In Remission at Week 1238.833.323.5
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared, Corrected · p = 0.083 · Odds ratio (or): 2.060 · 95% CI 0.98 to 4.34
  • Apremilast 20 mg BID vs Placebo · Chi-squared, Corrected · p = 0.279 · Odds ratio (or): 1.630 · 95% CI 0.77 to 3.44
SecondaryPercentage of Participants With DAS28-CRP(3) Score of Mild Disease Activity or In Remission at Week 12

The DAS28-CRP(3) measures the severity of disease derived from the following 3 variables: • 28 tender joint count (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) DAS28-CRP(3) scores range from 0 to 9.4, where higher scores indicate more disease activity. Mild disease severity is defined as a DAS28-CRP(3) score of ≤ 3.2. In remission is defined as a DAS28-CRP(3) score of ≤ 2.6.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With DAS28-CRP(3) Score of Mild Disease Activity or In Remission at Week 12
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Percentage of Participants With DAS28-CRP(3) Score of Mild Disease Activity or In Remission at Week 1240.334.833.8
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared, Corrected · p = 0.548 · Odds ratio (or): 1.320 · 95% CI 0.66 to 2.66
  • Apremilast 20 mg BID vs Placebo · Chi-squared, Corrected · p = 1.000 · Odds ratio (or): 1.040 · 95% CI 0.52 to 2.11
SecondaryNumber of Participants Who Withdrew Prematurely Due to Lack of Efficacy

The number of participants who withdrew prematurely from the treatment phase due to lack of efficacy, including flare of psoriasis, flare of psoriatic arthritis or worsening or not responding to study treatment.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Withdrew Prematurely Due to Lack of Efficacy
ParticipantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Number of Participants Who Withdrew Prematurely Due to Lack of Efficacy0612
SecondaryNumber of Participants With Adverse Events Leading to a Dose Reduction

The number of participants who were dose reduced during the treatment phase due to adverse events.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to a Dose Reduction
ParticipantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Number of Participants With Adverse Events Leading to a Dose Reduction440
SecondaryMaximal ACR Response During the Treatment Phase

The ACR-N index score was calculated for each participant at each time point in the study according to the following definition: ACR-N = the lowest of the following 3 values: - percent improvement from Baseline in the 76 swollen joint count, - percent improvement from Baseline in the 78 tender joint count - median percent improvement from Baseline in the following 5 measures ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. The maximal ACR-N for each participant during the 12-week treatment period was calculated, and represents the maximal ACR response achieved.

Time frame:
ACR was measured at Baseline and Weeks 2, 4, 6, 8, 10, and 12
Reported as:
Mean · percent improvement
Maximal ACR Response During the Treatment Phase
percent improvementApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Maximal ACR Response During the Treatment Phase22.3 ± 56.4524.2 ± 37.6310.7 ± 35.42
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · ANOVA · p = 0.136 · Treatment difference: 11.58Treatment Difference = Apremilast 20 mg BID - Placebo
  • Apremilast 20 mg BID vs Placebo · ANOVA · p = 0.080 · Treatment difference: 13.53Treatment Difference = Apremilast 20 mg BID - Placebo
SecondaryTime to ACR 20 Response During the Treatment Phase

The Kaplan-Meier estimates of time to ACR 20 response was calculated for participants who had an ACR 20 response at any time during the treatment phase.

Time frame:
Baseline to Week 12
Reported as:
Median · days
Time to ACR 20 Response During the Treatment Phase
daysApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Time to ACR 20 Response During the Treatment Phase29.0 (29.0 to 43.0)30.0 (29.0 to 57.0)29.0 (20.0 to 47.0)
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared · p = 0.650 · Hazard ratio (hr): 0.950 · 95% CI 0.745 to 1.211Based on a proportional hazards model comparing the hazard functions associated with the treatment and placebo.
  • Apremilast 20 mg BID vs Placebo · Chi-squared · p = 0.283 · Hazard ratio (hr): 1.265 · 95% CI 0.791 to 2.024Based on a proportional hazards model comparing the hazard functions associated with the treatment and placebo.
SecondaryTime to ACR 50 Response During the Treatment Phase

The Kaplan-Meier estimates of time to ACR 50 response was calculated for participants who had an ACR 50 response at any time during the treatment phase.

Time frame:
Baseline to Week 12
Reported as:
Median · days
Time to ACR 50 Response During the Treatment Phase
daysApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Time to ACR 50 Response During the Treatment Phase43.0 (29.0 to 61.0)57.5 (56.0 to 72.0)15.0 (14.0 to 73.0)
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared · p = 0.253 · Hazard ratio (hr): 1.337 · 95% CI 0.791 to 2.260Based on a proportional hazards model comparing the hazard functions associated with the treatment and placebo.
  • Apremilast 20 mg BID vs Placebo · Chi-squared · p = 0.026 · Hazard ratio (hr): 3.023 · 95% CI 1.059 to 8.630Based on a proportional hazards model comparing the hazard functions associated with the treatment and placebo.
SecondaryTime to ACR 70 Response During the Treatment Phase

The Kaplan-Meier estimates of time to ACR 70 response was calculated for participants who had an ACR 70 response at any time during the treatment phase.

Time frame:
Baseline to Week 12
Reported as:
Median · days
Time to ACR 70 Response During the Treatment Phase
daysApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Time to ACR 70 Response During the Treatment Phase62.0 (47.0 to 85.0)57.0 (43.0 to 85.0)58.0 (31.0 to 85.0)
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · Chi-squared · p = 0.984 · Hazard ratio (hr): 1.006 · 95% CI 0.457 to 2.215Based on a proportional hazards model comparing the hazard functions associated with the treatment and placebo.
  • Apremilast 20 mg BID vs Placebo · Chi-squared · p = 0.836 · Hazard ratio (hr): 0.872 · 95% CI 0.158 to 4.797Based on a proportional hazards model comparing the hazard functions associated with the treatment and placebo.
SecondaryChange From Baseline in Dactylitis Severity Score at Week 12

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated on a scale from 0 (no dactylitis) to 3 (severe dactylitis). The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 60.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Dactylitis Severity Score at Week 12
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Change From Baseline in Dactylitis Severity Score at Week 12-0.9 ± 2.39-1.2 ± 3.11-0.2 ± 3.75
SecondaryPercentage of Participants With Enthesitis

Enthesitis is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Enthesitis is characterized by swelling, pain, and tenderness around the calcaneous, and occasionally by effusion in the bursa associated with this joint. The enthesitis assessment is an evaluation of inflammation at the insertions of the Achilles tendon into the calcaneous and of the plantar fascia into the calcaneous. Inflammation at 1 or more insertions on either the right or left side constituted a positive assessment.

Time frame:
Baseline and Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Enthesitis
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Achilles tendon into the calcaneous: Baseline22.421.735.3
Achilles tendon into the calcaneous: Week 1220.917.417.6
Plantar fascia into the calcaneous: Baseline26.926.114.7
Plantar fascia into the calcaneous: Week 1219.421.717.6
SecondaryTime to Relapse of Psoriatic Arthritis During the Observational Follow-up Phase

Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Observation Phase in participants who received apremilast and achieved at least an ACR 20 at their Final Treatment Phase/Early Termination Visit. The time to relapse during the Observational Phase was calculated from the time of maximum ACR reduction and from the date of the Final Treatment Phase visit. Participants classified as responders who did not relapse were censored at the day of the last follow-up.

Time frame:
From Week 12 to end of 28-day observational follow-up (1) and from the date of maximal ACR during the 12-week Treatment Phase until the end of the 28-day observational follow-up phase (2).
Reported as:
Median · days
Time to Relapse of Psoriatic Arthritis During the Observational Follow-up Phase
daysApremilast 40 mg QDApremilast 20 mg BID
1. From Week 1216.0 (15.0 to 29.0)15.0 (14.0 to 29.0)
2. From Date of Maximal ACR Response43.0 (34.0 to 73.0)29.0 (22.0 to 43.0)
SecondaryNumber of Participants Who Relapsed During the Observational Follow-up Phase

Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Observation Phase in participants who received apremilast and achieved at least an ACR 20 at their Final Treatment Phase/Early Termination Visit.

Time frame:
28-day observational follow-up period following Week 12
Reported as:
Count of participants · Participants
Number of Participants Who Relapsed During the Observational Follow-up Phase
ParticipantsApremilast 40 mg QDApremilast 20 mg BID
Number of Participants Who Relapsed During the Observational Follow-up Phase59
SecondaryChange From Baseline in Short Form 36 (SF-36) Summary Physical and Mental Component Scores at Week 12

The Medical Outcome SF 36-Item Health Survey, Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The summary physical health score included the following subscales: physical functioning, role-physical, bodily pain, and general health. The summary mental health score included other subscales: vitality, social functioning, role-emotional, and mental health. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10, where higher scores are associated with better functioning/quality of life. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale. A higher change from baseline indicates an improvement in better health results or functioning.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Short Form 36 (SF-36) Summary Physical and Mental Component Scores at Week 12
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Mental Component1.0 ± 8.013.4 ± 7.18-0.8 ± 8.39
Physical Component2.1 ± 5.942.4 ± 7.890.8 ± 6.24
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · ANOVA · p = 0.308 · Adjusted mean difference: 1.4Adjusted mean difference (Apremilast-Placebo) was based on the ANOVA model described above.
  • Apremilast 20 mg BID vs Placebo · ANOVA · p = 0.003 · Adjusted mean difference: 4.1Adjusted mean difference (Apremilast-Placebo) was based on the ANOVA model described above.
  • Apremilast 40 mg QD vs Placebo · ANOVA · p = 0.182 · Adjusted mean difference: 1.6Adjusted mean difference (Apremilast-Placebo) was based on the ANOVA model described above.
  • Apremilast 20 mg BID vs Placebo · ANOVA · p = 0.026 · Adjusted mean difference: 2.7Adjusted mean difference (Apremilast-Placebo) was based on the ANOVA model described above.
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) at Week 12

The DLQI is a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on participants' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Each question is answered on a scale from 0 (not at all) to 3 (very much). The total score ranges from 0 to 30 where a higher score indicates that a participant's dermatological condition has a greater impact on their daily life.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12-2.6 ± 5.96-1.8 ± 4.29-0.3 ± 4.82
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · ANOVA · p = 0.016 · Adjusted mean difference: -2.1The adjusted mean difference (Apremilast-Placebo) is based on an ANOVA model described above.
  • Apremilast 20 mg BID vs Placebo · ANOVA · p = 0.105 · Adjusted mean difference: -1.4The adjusted mean difference (Apremilast-Placebo) is based on an ANOVA model described above.
SecondaryChange From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12

The HAQ-DI is a self-administered instrument consisting of 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item asks over the past week whether a particular task can be performed. For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). The eight category scores are averaged into an overall HAQ-DI score on a scale from zero (no disability) to three (completely disabled).

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Change From Baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12-0.2 ± 0.39-0.2 ± 0.35-0.1 ± 0.39
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 12

The FACIT-Fatigue is a 13 item self-administered questionnaire that assesses both the physical and functional consequences of fatigue based on recall during the past 7 days. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The total score ranges from 0 to 52 with higher scores representing less fatigue.

Time frame:
Baseline and Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 12
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo
Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 124.3 ± 9.464.1 ± 8.780.5 ± 8.03
Statistical analysis
  • Apremilast 40 mg QD vs Placebo · ANOVA · p = 0.028 · Adjusted mean difference: 3.3The adjusted mean difference (Apremilast-Placebo) is based on an ANOVA model described above.
  • Apremilast 20 mg BID vs Placebo · ANOVA · p = 0.004 · Adjusted mean difference: 4.3The adjusted mean difference (Apremilast-Placebo) is based on an ANOVA model described above.
SecondaryNumber of Participants With Adverse Events During the Extension Phase

The severity of each adverse event (AE) was graded based upon the participant's symptoms according to National Cancer Institute (NCI) Common Toxicity Criteria (CTCAE, Version 3.0), on a scale from 1 (Mild AE) to 5 (Death due to AE). Severe AEs are defined as NCI CTCAE grade 3 or higher. AEs related to study drug are those determined by the investigator as suspected to be related to study drug where a temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other medications, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. A serious adverse event (SAE) is any AE which: - Resulted in death - Was life-threatening - Required inpatient hospitalization or prolongation of existing hospitalization - Resulted in persistent or significant disability/incapacity - Was a congenital anomaly/birth defect - Constituted an important medical event.

Time frame:
Weeks 12 to 24 (Extension Phase)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events During the Extension Phase
ParticipantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
All adverse events30291611
Adverse events related to study drug12844
Severe adverse events5334
Serious adverse events2311
Serious adverse events related to study drug0001
Discontinued study drug due to adverse event3203
Discontinued due to AE related to study drug1101
SecondaryPercentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

A PsARC response is defined as improvement from Baseline in at least 2 of the following 4 measures, at least 1 of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • At least 30% improvement in the 78 tender joint count, • At least 30% improvement in the 76 swollen joint count, • At least 20% improvement in the patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0 mm = lowest disease activity and 100 mm = highest; • At least 20% improvement in the physician global assessment of disease activity, measured on a 100 mm VAS, where 0 mm = lowest disease activity and 100 mm = highest. Participants with missing data were considered non-responders.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Percentage of Participants With a Psoriatic Arthritis Response Criteria (PsARC) Response at Week 2426.120.055.040.0
SecondaryPercentage of Participants With a Modified ACR 20 Response at Week 24

A modified ACR 20 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 20% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1) and from Week 12 (Day 85). Participants with no post-baseline ACR scores were considered non-responders.

Time frame:
Baseline (Day 1), Week 12 (Day 85) and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified ACR 20 Response at Week 24
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Response From Baseline43.542.545.040.0
Response From Week 1216.714.715.416.7
SecondaryPercentage of Participants With a Modified ACR 50 Response at Week 24

A modified ACR 50 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 50% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1) and from Week 12 (Day 85). Participants with no post-baseline ACR scores were considered non-responders.

Time frame:
Baseline (Day 1), Week 12 (Day 85) and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified ACR 50 Response at Week 24
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Response From Baseline23.922.520.015.0
Response From Week 129.75.915.45.6
SecondaryPercentage of Participants With a Modified ACR 70 Response at Week 24

A modified ACR 70 response was defined as a participant who met the following 3 criteria for improvement: • ≥ 70% improvement in 78 tender joint count (includes 10 additional joints often involved in psoriatic arthritis: the first carpometacarpal \[CMC\] and the distal interphalangeal \[DIP\] joints of the fingers); • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm VAS); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. Response at Week 24 was measured as improvement from Baseline (Day 1). Participants with no post-baseline ACR scores were considered non-responders.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified ACR 70 Response at Week 24
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Percentage of Participants With a Modified ACR 70 Response at Week 2413.017.515.05.0
SecondaryPercentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(4) at Week 24

The DAS28 measures the severity of disease at a specific time. DAS28-CRP(4) is derived from the following 4 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein • Patient's global assessment of disease activity according to the formula: DAS28-CRP(4) = 0.56\*√(TJC28) + 0.28\*(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(4) at Week 24
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(4) at Week 2467.460.070.050.0
SecondaryPercentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 24

The DAS28 measures the severity of disease at a specific time. DAS28-CRP(3) is derived from the following 3 variables: • 28 tender joint count, (does not include the DIP joints, the hip joint, or the joints below the knee) • 28 swollen joint count • C-reactive protein (CRP) according to the formula: DAS28-CRP(3) = \[0.56\*√(TJC28) + 0.28\*√(SJC28) + 0.36\*ln(CRP+1)\] \* 1.10 + 1.15. DAS28 scores range from 0 to 9.4, where higher scores indicate more disease activity. A EULAR response reflects an improvement in disease activity based on the DAS-28 score. A Good Response is defined as an improvement (decrease) in the DAS28 \> 1.2 from Baseline and attainment of a DAS28 score ≤ 3.2. A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 \> 0.6 and ≤ 1.2 and a DAS28 score ≤ to 5.1 or, • an improvement (decrease) in the DAS28 \> 1.2 and a DAS28 score \> 3.2

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 24
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Percentage of Participants With Good or Moderate EULAR Response Based on DAS28-CRP(3) at Week 2460.967.565.055.0
SecondaryMaximal ACR Response During the Extension Period

The ACR-N index score was calculated for each participant at each time point in the study according to the following definition: ACR-N = the lowest of the following 3 values: • percent improvement from Baseline in the 76 swollen joint count, • percent improvement from Baseline in the 78 tender joint count • median percent improvement from Baseline in the following 5 measures ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); ◦ Patient's global assessment of disease activity (measured on a 100 mm VAS); ◦ Physician's global assessment of disease activity (measured on a 100 mm VAS); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\]); ◦ C-reactive protein. The maximal ACR-N for each participant during the 12-week extension period was calculated, and represents the maximal ACR response achieved.

Time frame:
ACR was measured at Baseline and Weeks 16, 20 and 24
Reported as:
Mean · percent improvement
Maximal ACR Response During the Extension Period
percent improvementApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Maximal ACR Response During the Extension Period29.1 ± 40.8630.4 ± 36.7723.3 ± 32.1134.2 ± 31.16
SecondaryTime to ACR 20 Response During the Study

Time to ACR 20 was measured from the first dose of apremilast to the first time a participant achieved an ACR 20 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 20 response were calculated for participants who had an ACR 20 response at any time during the study.

Time frame:
Baseline to Week 24
Reported as:
Median · days
Time to ACR 20 Response During the Study
daysApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Time to ACR 20 Response During the Study43.0 (29.0 to 44.0)43.0 (29.0 to 59.0)34.0 (29.0 to 55.0)55.5 (29.0 to 57.0)
SecondaryTime to ACR 50 Response During the Treatment and Extension Phase

Time to ACR 50 response was measured from the first dose of apremilast to the first time a participant achieved an ACR 50 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 50 response were calculated for participants who had an ACR 50 response at any time during the study.

Time frame:
Baseline to Week 24
Reported as:
Median · days
Time to ACR 50 Response During the Treatment and Extension Phase
daysApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Time to ACR 50 Response During the Treatment and Extension Phase71.0 (44.0 to 110.0)58.5 (56.0 to 86.0)84.5 (84.0 to 85.0)55.0 (23.0 to 57.0)
SecondaryTime to ACR 70 Response During the Treatment and Extension Phase

Time to ACR 70 response was measured from the first dose of apremilast to the first time a participant achieved an ACR 70 response in the treatment or extension phase. The Kaplan-Meier estimates of time to ACR 70 response were calculated for participants who had an ACR 70 response at any time during the study.

Time frame:
Baseline to Week 24
Reported as:
Median · days
Time to ACR 70 Response During the Treatment and Extension Phase
daysApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Time to ACR 70 Response During the Treatment and Extension Phase138.0 (85.0 to 169.0)85.0 (57.0 to 141.0)——
SecondaryChange From Baseline and Week 12 in Dactylitis Severity Score at Week 24

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated on a scale from 0 (no dactylitis) to 3 (severe dactylitis). The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 60. Change in the dactylitis severity score was assessed from Baseline (Day 1) and from Week 12 (Day 85).

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · units on a scale
Change From Baseline and Week 12 in Dactylitis Severity Score at Week 24
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Change from Baseline-0.4 ± 3.47-1.5 ± 3.13-1.8 ± 4.940.1 ± 1.08
Change from Week 120.3 ± 3.07-0.2 ± 1.97-0.3 ± 0.98-0.8 ± 2.39
SecondaryPercentage of Participants With Enthesitis in the Extension Phase

Enthesitis is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. Enthesitis is characterized by swelling, pain, and tenderness around the calcaneous, and occasionally by effusion in the bursa associated with this joint. The enthesitis assessment is an evaluation of inflammation at the insertions of the Achilles tendon into the calcaneous and of the plantar fascia into the calcaneous. Inflammation at 1 or more insertions on either the right or left side constituted a positive assessment.

Time frame:
Week 12 and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Enthesitis in the Extension Phase
percentage of participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Achilles tendon into the calcaneous: Week 1217.415.020.020.0
Achilles tendon into the calcaneous: Week 2419.615.00.015.0
Plantar fascia into the calcaneous:Week 1215.217.525.010.0
Plantar fascia into the calcaneous: Week 2413.07.50.010.0
SecondaryTime to Relapse of Psoriatic Arthritis After Extension Phase

Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Follow-up Phase in participants who achieved at least an ACR 20 at their Final Extension Phase (Week 24)/Early Termination Visit. The time to relapse during the Follow-up Phase was calculated from the time of maximum ACR reduction and from the date of the Final Extension Phase visit. Participants classified as responders who did not relapse were censored at the day of the last follow-up.

Time frame:
From Week 24 to the end of the 28-day follow-up (1) and from the date of maximal ACR until the end of the 28-day follow-up phase (2).
Reported as:
Median · days
Time to Relapse of Psoriatic Arthritis After Extension Phase
daysApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
1. From Week 1231.0 (29.0 to NA)32.0 (29.0 to 38.0)16.0 (NA to NA)29.0 (15.0 to NA)
2. From Date of Maximal ACR Response85.0 (57.0 to NA)111 (41.0 to NA)16.0 (NA to NA)29.0 (15.0 to NA)
SecondaryNumber of Participants Who Relapsed After the Extension Phase

Relapse of psoriatic arthritis was defined as a 50% loss of the maximal ACR improvement during the Follow-up Phase in participants who achieved at least an ACR 20 at their Final Extension Phase/Early Termination Visit.

Time frame:
Week 24 to Week 28 (28-day follow-up period)
Reported as:
Number · participants
Number of Participants Who Relapsed After the Extension Phase
participantsApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Number of Participants Who Relapsed After the Extension Phase8812
SecondaryChange From Baseline and Week 12 in SF-36 at Week 24

The Medical Outcome SF 36-Item Health Survey, Version 2 is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The summary physical health score included the following subscales: physical functioning, role-physical, bodily pain, and general health. The summary mental health score included other subscales: vitality, social functioning, role-emotional, and mental health. Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10, where higher scores are associated with better functioning/quality of life. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale. A higher change from baseline indicates an improvement in better health results or functioning.

Time frame:
Baseline (Day 1), Week 12 (Day 85) and Week 24
Reported as:
Mean · units on a scale
Change From Baseline and Week 12 in SF-36 at Week 24
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Mental Component: Change from Baseline0.2 ± 9.081.4 ± 8.92-2.7 ± 12.20-1.0 ± 14.00
Mental Component: Change from Week 12-1.1 ± 8.14-2.4 ± 9.35-2.5 ± 10.60-3.4 ± 10.61
Physical Component: Change from Baseline3.2 ± 6.684.4 ± 7.741.8 ± 9.504.2 ± 9.99
Physical Component: Change from Week 120.3 ± 6.101.0 ± 6.60-0.1 ± 8.502.5 ± 7.81
SecondaryChange From Baseline and Week 12 in Dermatology Life Quality Index (DLQI) at Week 24

The DLQI is a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on participants' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, leisure, work, personal relationships, and treatment. Each question is answered on a scale from 0 (not at all) to 3 (very much) The total score ranges from 0 to 30 where a higher score indicates that a participant's dermatological condition has a greater impact on their daily life.

Time frame:
Baseline (Day 1), Week 12 (Day 85) and Week 24
Reported as:
Mean · units on a scale
Change From Baseline and Week 12 in Dermatology Life Quality Index (DLQI) at Week 24
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Change from Baseline-3.0 ± 7.36-1.5 ± 4.08-2.6 ± 4.78-1.9 ± 5.50
Change from Week 12-0.0 ± 5.72-0.1 ± 3.54-1.2 ± 2.07-2.0 ± 6.25
SecondaryChange From Baseline and Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24

The HAQ-DI is a self-administered instrument consisting of 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item asks over the past week whether a particular task can be performed. For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). The eight category scores are averaged into an overall HAQ-DI score on a scale from zero (no disability) to three (completely disabled).

Time frame:
Baseline (Day 1), Week 12 (Day 85) and Week 24
Reported as:
Mean · units on a scale
Change From Baseline and Week 12 in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Change from Baseline-0.1 ± 0.45-0.2 ± 0.37-0.1 ± 0.61-0.2 ± 0.59
Change from Week 120.0 ± 0.37-0.0 ± 0.23-0.0 ± 0.46-0.2 ± 0.44
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 24

The FACIT-Fatigue is a 13 item self-administered questionnaire that assesses both the physical and functional consequences of fatigue based on recall during the past 7 days. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The total score ranges from 0 to 52 with higher scores representing less fatigue.

Time frame:
Baseline (Day 1), Week 12 (Day 85) and Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F) at Week 24
units on a scaleApremilast 40 mg QDApremilast 20 mg BIDPlacebo/Apremilast 40 mg QDPlacebo/Apremilast 20 mg BID
Change from Baseline4.4 ± 9.765.9 ± 7.761.3 ± 11.231.3 ± 12.34
Change from Week 12-0.3 ± 8.560.1 ± 6.19-2.4 ± 9.05-1.3 ± 13.10

Adverse events

Collected over Adverse events are reported for the 12-week placebo-controlled phase, including AEs that occurred during the 28-day observational follow-up, and for up to 24 weeks for all participants who were randomized or re-randomized to apremilast at any time during the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Week 12: Apremilast 40 mg QD—0/67 (0%)45/67 (67.2%)
Week 12: Apremilast 20 mg BID—4/69 (5.8%)44/69 (63.8%)
Week 12: Placebo—6/68 (8.8%)42/68 (61.8%)
Week 24: Apremilast 40 mg QD—3/87 (3.4%)63/87 (72.4%)
Week 24: Apremilast 20 mg BID—8/89 (9%)62/89 (69.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventWeek 12: Apremilast 40 mg QDWeek 12: Apremilast 20 mg BIDWeek 12: PlaceboWeek 24: Apremilast 40 mg QDWeek 24: Apremilast 20 mg BID
NauseaGastrointestinal disorders0/670/692/680/870/89
VomitingGastrointestinal disorders0/670/691/680/870/89
ArthralgiaMusculoskeletal and connective tissue disorders0/670/691/680/870/89
Psoriatic arthropathyMusculoskeletal and connective tissue disorders0/670/691/680/870/89
FallInjury, poisoning and procedural complications0/670/691/680/870/89
Balance disorderNervous system disorders0/670/691/680/870/89
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/670/691/680/870/89
Intervertebral disc degenerationMusculoskeletal and connective tissue disorders0/671/690/680/871/89
Sinus tachycardiaCardiac disorders0/671/690/680/871/89
Biliary colicHepatobiliary disorders0/671/690/680/871/89
Most frequent other events
Showing 10 of 19
Most frequent other events
EventWeek 12: Apremilast 40 mg QDWeek 12: Apremilast 20 mg BIDWeek 12: PlaceboWeek 24: Apremilast 40 mg QDWeek 24: Apremilast 20 mg BID
DiarrhoeaGastrointestinal disorders18/6714/697/6823/8714/89
NasopharyngitisInfections and infestations8/678/6914/6823/8718/89
NauseaGastrointestinal disorders15/6712/6910/6823/8714/89
HeadacheNervous system disorders15/6713/6911/6817/8717/89
FatigueGeneral disorders11/676/696/6811/877/89
Psoriatic arthropathyMusculoskeletal and connective tissue disorders5/677/698/6810/8713/89
DizzinessNervous system disorders7/673/693/687/873/89
Abdominal pain upperGastrointestinal disorders4/677/693/685/878/89
MigraineNervous system disorders2/676/690/683/876/89
PruritusSkin and subcutaneous tissue disorders5/672/691/685/874/89

Baseline characteristics

Age, Continuous
Age, Continuous(years)Apremilast 40 mg QDApremilast 20 mg BIDPlaceboTotal
Mean49.9 ± 11.1750.9 ± 12.5851.1 ± 10.8050.6 ± 11.50
Sex: Female, Male
Sex: Female, Male(Participants)Apremilast 40 mg QDApremilast 20 mg BIDPlaceboTotal
Female35263697
Male324332107
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Apremilast 40 mg QDApremilast 20 mg BIDPlaceboTotal
White626768197
Black1001
Hispanic1001
Asian/Pacific Islander2103
American Indian/Alaska Native0000
Other1102
Psoriatic Arthritis Disease Category
Psoriatic Arthritis Disease Category(Participants)Apremilast 40 mg QDApremilast 20 mg BIDPlaceboTotal
Asymmetrical Oligoarthritis26212067
Predominant Spondylitis4329
Symmetric Polyarthritis323639107
Arthritis Mutilans2057
Predominant Distal Interphalgeal Involvement29213
Missing/Unknown1001
Duration of Psoriatic Arthritis
Duration of Psoriatic Arthritis(years)Apremilast 40 mg QDApremilast 20 mg BIDPlaceboTotal
Mean7.6 ± 8.738.4 ± 9.777.3 ± 6.747.8 ± 8.48
Pain/Tender Joint Score
Pain/Tender Joint Score(joints)Apremilast 40 mg QDApremilast 20 mg BIDPlaceboTotal
Mean23.2 ± 17.6320.6 ± 15.9021.3 ± 15.5521.7 ± 16.33
Swollen Joint Score
Swollen Joint Score(joints)Apremilast 40 mg QDApremilast 20 mg BIDPlaceboTotal
Mean8.4 ± 4.9410.6 ± 9.889.5 ± 9.689.5 ± 8.51
Psoriasis Severity
Psoriasis Severity(Participants)Apremilast 40 mg QDApremilast 20 mg BIDPlaceboTotal
None271221
Mild414740128
Moderate20151146
Severe4059

2 further baseline measures are reported on the registry.

08

Study locations

38 sites
  • CHU Brugmann
    Brussels, 1020, Belgium
  • Universiteit Hasselt
    Diepenbeek, 3590, Belgium
  • University Hospital
    Leuven, 3000, Belgium
  • Jan Palfijn Ziekenhuis
    Merksem, 2170, Belgium
  • The Arthritis Research Centre of Canada
    Vancouver, British Columbia V5Z 1L7, Canada
  • Victoria, British Columbia V8P4Y3, Canada
  • Nexus Clinical Research
    St Johns, Newfoundland and Labrador A1B 3E1, Canada
  • Burlington Rheumatology and Osteoporosis Clinic
    Burlington, Ontario L7R 4B7, Canada
  • MAC Research Inc.
    Hamilton, Ontario L8N 2B6, Canada
  • K-W Musculoskeletal Research Inc.
    Kitchener, Ontario N2M 5N6, Canada
  • Credit Valley Rheumatology
    Mississauga, Ontario L5M 2V8, Canada
  • Arthritis Program Research Group Inc
    Newmarket, Ontario L3Y 3R7, Canada
  • Rheumatology Research Associates
    Ottawa, Ontario K1H 1A2, Canada
  • Center for Prognosis Studies in the Rheumatic Diseases University Health Network, Toronto Western Hospital
    Toronto, Ontario M5T 2S8, Canada
  • Mount Sinai Hospital
    Toronto, Ontario M5T 3L9, Canada
  • Probity Medical
    Waterloo, Ontario N2J1C4, Canada
  • Clinical Research and Arthritis Centre
    Windsor, Ontario N8X 5A6, Canada
  • West Island Rheumatology Research Associates
    Pointe-Claire, Quebec, Canada
  • Saskatoon Osteoporosis Center
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Capio Franz von Prümmer Klinik
    Bad Brückenau, 97769, Germany
  • Free University of Berlin
    Berlin, 10117, Germany
  • Universitaetsklinikum Frankfurt
    Frankfurt, 60590, Germany
  • Klinikum Eilbek
    Hamburg, 22081, Germany
  • Universitaet Heidelberg
    Heidelberg, 69120, Germany
  • Rheumazentrum Ruhrgebiet
    Herne, 44652, Germany
  • Universitaetsklinik Koeln
    Koeln, 50924, Germany
  • Universitaet Leipzig
    Leipzig, 04103, Germany
  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • University of Munich
    Munich, 80336, Germany
  • Klinikum der Universität Munster
    Munster, 48149, Germany
  • Friedrich-Alexander University, Erlangen
    Nuremberg, 91054, Germany
  • Hagaziekenhuis
    Den Haag, 2454 CH, Netherlands
  • Leiden University Medical Centre
    Leiden, 2300, Netherlands
  • Radboud University
    Nijmegen, 6500, Netherlands
  • Hope Hospital
    Salford, Manchester M6 8HD, United Kingdom
  • Haywood Hospital
    Stoke on Trent, Staffs ST6 7AG, United Kingdom
  • Chapel Allerton Hospital
    Leeds, LS7 4SA, United Kingdom
  • Freeman Hospital
    Newcastle-upon-Tyne, NE7 7DN, United Kingdom
09

References and documents

Publications

  • Schett G, Wollenhaupt J, Papp K, Joos R, Rodrigues JF, Vessey AR, Hu C, Stevens R, de Vlam KL. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012 Oct;64(10):3156-67. doi: 10.1002/art.34627. PubMed 22806399 ↗
  • Strand V, Schett G, Hu C, Stevens RM. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol. 2013 Jul;40(7):1158-65. doi: 10.3899/jrheum.121200. Epub 2013 Apr 15. PubMed 23588944 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2007 to primary completion in May 2009, 26 months.

Results were first posted in Oct 2019, 10 years 5 months after primary completion. A results delay was requested in Mar 2013.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2007
First posted
Apr 4, 2007
StartActual
Mar 5, 2007
Primary completionActual
May 9, 2009
CompletionActual
May 9, 2009
Results delay requested
Mar 28, 2013
Results first posted
Oct 23, 2019
Last update
Jun 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00456092
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 4, 2007
Start date
Mar 5, 2007
Primary completion
May 9, 2009
Completion
May 9, 2009
Results posted
Oct 23, 2019
Last update
Jun 19, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion